Abner Antonio Murray and Helena Yu
Jun 3, 2025, 04:59
Abner Antonio Murray: Helena Yu Presented Promising Data for Zipalertinib in Previously Treated EGFR ex20ins NSCLC at ASCO25
Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post on X:
“At ASCO25, Dr. Helena Yu presented promising data for zipalertinib in previously treated EGFR ex20ins NSCLC
In this phase 1/2 study, zipalertinib showed:
ORR 35% (95% CI: 28–43%)
Clinical activity post-platinum ± amivantamab
ORR 24% even in the post-amivantamab group
CNS activity (ORR 31% in pts w/ brain mets)
Durable responses: median DOR 8.8 mo
Manageable safety, consistent with prior data
A potential option for a population with high unmet need. RESILIENT3, a phase 3 1L trial, is ongoing.”
More posts featuring Abner Antonio Murray.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 19:30
Jun 26, 2025, 17:54
Jun 26, 2025, 17:47